Skip to main content

Table 1 Metastases formation in the orthotopic pancreatic cancer xenogeneic and syngeneic model

From: Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model

L3.6pl orthotopic model1
  Liver metastases LN metastases
Positive Negative Positive Negative
Control (n = 12) 8 (66.7%) 4 (33.3%) 8 (66.7%) 4 (33.3%)
INC280 10 mg/kg/d (n = 10) 5 (50%) 5 (50%) 3 (30%) 7 (70%)
INC280 20 mg/kg/d (n = 8) 4 (50%) 4 (50%) 2 (25%) 6 (75%)
Panc02 orthotopic model 2
  LN metastases Ascites
Positive Negative Positive Negative
Control (n = 7) 4 (57.1%) 3 (42.9%) 4 (57.1%) 3 (42.9%)
INC280 10 mg/kg/d (n = 7) 0 7 (100%) 0 7 (100%)
Panc02 orthotopic model 2
  LN metastases Ascites
Positive Negative Positive Negative
Control (n = 9) 6 (66.7%) 3 (33.3%) 3 (33.3%) 6 (66.7%)
INC280 (n = 7) 1 (14.3%) 6 (85.7%) 1 (14.3%) 6 (85.7%)
gemcitabine (n = 8) 2 (25%) 6 (75%) 2 (25%) 6 (75%)
INC280 + gemcitabine (n = 8) 1 (12.5%) 7 (87.5%)* 0 (0%) 8 (100%)
  1. 1does not form ascites in our hands.
  2. 2does not form liver metastases in our hands.
  3. *P < 0.05 vs. control.